BCRX Overview
Upcoming Projects (BCRX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (BCRX)
-
A Second View: Looking at Biocryst's BCX9930 (oral Factor D inhibitor) for the treatment in patients with C3 Glomerulopathy
Ticker: BCRX
Executed On: Oct 04, 2022 at 02:00 PM EDT -
Looking at Biocryst's BCX9930 (oral Factor D inhibitor) for the treatment in patients with C3 Glomerulopathy
Ticker: BCRX
Executed On: Sep 30, 2022 at 01:30 PM EDT -
A third discussion of the clinical landscape of Hereditary Angioedema, with a focus on the phase 1/2 results of Intellia's CRISPR treatment, NTLA-2002
Tickers: NTLA, BCRX, IONS, TAK
Executed On: Sep 23, 2022 at 03:00 PM EDT -
A second discussion of the clinical landscape of Hereditary Angioedema, with a focus on the phase 1/2 results of Intellia's CRISPR treatment, NTLA-2002
Tickers: NTLA, BCRX, IONS, TAK
Executed On: Sep 23, 2022 at 02:00 PM EDT -
Discussing the clinical landscape of Hereditary Angioedema, with a focus on the phase 1/2 results of Intellia's CRISPR treatment, NTLA-2002
Tickers: NTLA, BCRX, IONS, TAK
Executed On: Sep 22, 2022 at 12:00 PM EDT -
A final look at the use of preventative hereditary angioedema(HAE) treatments such as Haegarda, Orladeyo, and Takhzyro, as well as the potential of Donidalorsen in HAE.
Tickers: BCRX, IONS, TAK, CSLLY
Executed On: Jul 26, 2022 at 06:00 PM EDT -
A Third look at the use of preventative hereditary angioedema(HAE) treatments such as Haegarda, Orladeyo, and Takhzyro, as well as the potential of Donidalorsen in HAE.
Tickers: BCRX, IONS, TAK, CSLLY
Executed On: Jul 22, 2022 at 01:15 PM EDT -
A Second look at the use of preventative hereditary angioedema(HAE) treatments such as Haegarda, Orladeyo, and Takhzyro, as well as the potential of Donidalorsen in HAE.
Tickers: BCRX, IONS, TAK, CSLLY
Executed On: Jul 22, 2022 at 12:00 PM EDT -
A look at the use of preventative hereditary angioedema(HAE) treatments such as Haegarda, Orladeyo, and Takhzyro, as well as the potential of Donidalorsen in HAE.
Tickers: BCRX, TAK, IONS, CSLLY
Executed On: Jul 22, 2022 at 08:15 AM EDT -
A Second Opinion: Checking on the Orladeyo launch and potential in HAE
Ticker: BCRX
Executed On: Feb 14, 2022 at 05:15 PM EST -
Discussing the launch of Orladeyo in treating Hereditary Angioedema (HAE)
Ticker: BCRX
Executed On: Feb 11, 2022 at 08:15 PM EST
Upcoming & Overdue Catalysts (BCRX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (BCRX)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
